A Review of Muscle Relaxants in Anesthesia in Patients with Neuromuscular Disorders Including Guillain-Barré Syndrome, Myasthenia Gravis, Duchenne Muscular Dystrophy, Charcot-Marie-Tooth Disease, and Inflammatory Myopathies

Overview

Journal Med Sci Monit

Specialties General Medicine
Pathology

Date 2024 Dec 2

PMID 39618072

Authors

Pawel Radkowski

Hubert Oniszczuk

Justyna Opolska

Iwona Podlinska

Mateusz Pawluczuk

Dariusz Onichimowski

Affiliations

Soon will be listed here.

Abstract

Anesthesia management in neuromuscular diseases (NMDs) is a complex challenge, requiring careful preoperative evaluation, tailored treatment strategies, and vigilant perioperative monitoring. This review examines the nuances of anesthesia in patients with NMD, addressing potential complications such as intubation difficulties, respiratory failure, and adverse effects of anesthetics and neuromuscular conduction blocking agents (NMBAs). Nondepolarizing NMBAs, including steroidal agents and benzylisoquinolines, are analyzed for their role, risks, and optimal use based on procedural requirements and patient characteristics. Challenges with depolarizing agents such as succinylcholine are highlighted, emphasizing the need for careful evaluation and monitoring to reduce the risk of adverse events such as malignant hyperthermia and hyperkalemia. The review highlights the role of reversal agents, particularly sugammadex, as a safer and more effective alternative to traditional acetylcholinesterase inhibitors such as neostigmine. Sugammadex reduces the risk of complications such as prolonged paralysis and respiratory failure in patients with NMD. In addition, anesthesia considerations tailored to specific NMDs, including Guillain-Barre syndrome, myasthenia gravis, Duchenne muscular dystrophy, Charcot-Marie-Tooth disease, and inflammatory myopathies are presented, including monitoring techniques and individualized approaches. Based on the available literature and the authors' clinical experience, this review aims to discuss the role of muscle relaxants in anesthesia in patients with the aforementioned neuromuscular disorders. This document uses the latest possible articles, covering items from 1992 to 2024.

References

Ihmsen H, Viethen V, Forst J, Schwilden H, Schmitt H, Muenster T . Pharmacodynamic modelling of rocuronium in adolescents with Duchenne muscular dystrophy. Eur J Anaesthesiol. 2009; 26(2):105-10. DOI: 10.1097/eja.0b013e32831aed11. View

Kundal R, Singh P, Mansukhani M, Pandey M . Twin anaesthetic challenges in a patient recovered from Guillain-Barre syndrome. Indian J Anaesth. 2022; 66(6):479-480. PMC: 9316665. DOI: 10.4103/ija.ija_1006_21. View

Radkowski P, Suren L, Podhorodecka K, Harikumar S, Jamrozik N . A Review on the Anesthetic Management of Patients with Neuromuscular Diseases. Anesth Pain Med. 2023; 13(1):e132088. PMC: 10319043. DOI: 10.5812/aapm-132088. View

Fuchs-Buder T, Romero C, Lewald H, Lamperti M, Afshari A, Hristovska A . Peri-operative management of neuromuscular blockade: A guideline from the European Society of Anaesthesiology and Intensive Care. Eur J Anaesthesiol. 2022; 40(2):82-94. DOI: 10.1097/EJA.0000000000001769. View

Martyn J, Jonsson Fagerlund M, Eriksson L . Basic principles of neuromuscular transmission. Anaesthesia. 2009; 64 Suppl 1:1-9. DOI: 10.1111/j.1365-2044.2008.05865.x. View

Rockelein S, Gebert M, Baar H, Endsberger G . [Neuromuscular blockade with atracurium in dermatomyositis]. Anaesthesist. 1995; 44(6):442-4. DOI: 10.1007/s001010050174. View

Blais A . Succinylcholine, malignant hyperthermia and rhabdomyolysis. CMAJ. 2022; 194(25):E878. PMC: 9332916. DOI: 10.1503/cmaj.146480-l. View

Bartels K, Hunter J . Neostigmine versus sugammadex: the tide may be turning, but we still need to navigate the winds. Br J Anaesth. 2020; 124(5):504-507. DOI: 10.1016/j.bja.2020.02.021. View

Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A . Duchenne muscular dystrophy. Nat Rev Dis Primers. 2021; 7(1):13. PMC: 10557455. DOI: 10.1038/s41572-021-00248-3. View

10.

Visoiu M, Young M, Wieland K, Brandom B . Anesthetic drugs and onset of malignant hyperthermia. Anesth Analg. 2014; 118(2):388-396. DOI: 10.1213/ANE.0000000000000062. View

11.

Blobner M, Mann R . [Anesthesia in patients with myasthenia gravis]. Anaesthesist. 2001; 50(7):484-93. DOI: 10.1007/s001010100166. View

12.

Carey I, Banchoff E, Nirmalananthan N, Harris T, DeWilde S, Chaudhry U . Prevalence and incidence of neuromuscular conditions in the UK between 2000 and 2019: A retrospective study using primary care data. PLoS One. 2021; 16(12):e0261983. PMC: 8719665. DOI: 10.1371/journal.pone.0261983. View

13.

Schmitt H, Wick S, Munster T . Onset and duration of mivacurium-induced neuromuscular blockade in children with Charcot-Marie-Tooth disease. A case series with five children. Paediatr Anaesth. 2006; 16(2):182-7. DOI: 10.1111/j.1460-9592.2005.01627.x. View

14.

Grosse-Sundrup M, Henneman J, Sandberg W, Bateman B, Uribe J, Nguyen N . Intermediate acting non-depolarizing neuromuscular blocking agents and risk of postoperative respiratory complications: prospective propensity score matched cohort study. BMJ. 2012; 345:e6329. PMC: 3473088. DOI: 10.1136/bmj.e6329. View

15.

Bubuioc A, Kudebayeva A, Turuspekova S, Lisnic V, Leone M . The epidemiology of myasthenia gravis. J Med Life. 2021; 14(1):7-16. PMC: 7982252. DOI: 10.25122/jml-2020-0145. View

16.

Blichfeldt-Lauridsen L, Hansen B . Anesthesia and myasthenia gravis. Acta Anaesthesiol Scand. 2011; 56(1):17-22. DOI: 10.1111/j.1399-6576.2011.02558.x. View

17.

Pogson D, Telfer J, Wimbush S . Prolonged vecuronium neuromuscular blockade associated with Charcot Marie Tooth neuropathy. Br J Anaesth. 2001; 85(6):914-7. DOI: 10.1093/bja/85.6.914. View

18.

Shahrizaila N, Lehmann H, Kuwabara S . Guillain-Barré syndrome. Lancet. 2021; 397(10280):1214-1228. DOI: 10.1016/S0140-6736(21)00517-1. View

19.

Antognini J . Anaesthesia for Charcot-Marie-Tooth disease: a review of 86 cases. Can J Anaesth. 1992; 39(4):398-400. DOI: 10.1007/BF03009054. View

20.

Atluri R . Inflammatory Myopathies. Mo Med. 2016; 113(2):127-30. PMC: 6139945. View